Table 3 Selected postbaseline antineoplastic therapies
Non-rising PSA group (n=65) | Rising PSA group (n=200) | |
|---|---|---|
Patients taking any postbaseline antineoplastic therapy, n (%) | 31 (47.7) | 124 (62.0) |
Patients taking at least one of the following postbaseline antineoplastic therapies, n (%) | 30 (46.2) | 116 (58.0) |
Docetaxel | 24 (36.9) | 94 (47.0) |
Abiraterone acetate | 15 (23.1) | 56 (28.0) |
Cabazitaxel | 3 (4.6) | 20 (10.0) |
Sipuleucel-T | 0 | 6 (3.0) |
Enzalutamide | 1 (1.5) | 4 (2.0) |
